Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Jul;26(1):97–100. doi: 10.1128/aac.26.1.97

In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.

J T Rudrik, S J Cavalieri, E M Britt
PMCID: PMC179926  PMID: 6591853

Abstract

Enoxacin (CI-919) was evaluated for activity against 120 multiply resistant clinical isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa. The MIC of enoxacin for 95% of the strains tested was less than or equal to 2 micrograms/ml. Approximately 90% of the isolates were susceptible to enoxacin, norfloxacin, ceftazidime, moxalactam, cefotaxime, cefoperazone, and amikacin. Marked resistance to the other seven antimicrobial agents tested was observed.

Full text

PDF
97

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chartrand S. A., Scribner R. K., Weber A. H., Welch D. F., Marks M. I. In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound. Antimicrob Agents Chemother. 1983 May;23(5):658–663. doi: 10.1128/aac.23.5.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chin N. X., Neu H. C. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother. 1983 Nov;24(5):754–763. doi: 10.1128/aac.24.5.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kouno K., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activity of AT-2266. Antimicrob Agents Chemother. 1983 Jul;24(1):78–84. doi: 10.1128/aac.24.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Nakamura S., Kurobe N., Kashimoto S., Ohue T., Takase Y., Shimizu M. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother. 1983 Jul;24(1):54–60. doi: 10.1128/aac.24.1.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Nakamura S., Minami A., Katae H., Inoue S., Yamagishi J., Takase Y., Shimizu M. In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother. 1983 May;23(5):641–648. doi: 10.1128/aac.23.5.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Nakamura S., Nakata K., Katae H., Minami A., Kashimoto S., Yamagishi J., Takase Y., Shimizu M. Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice. Antimicrob Agents Chemother. 1983 May;23(5):742–749. doi: 10.1128/aac.23.5.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Shungu D. L., Weinberg E., Gadebusch H. H. Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715). Antimicrob Agents Chemother. 1983 Feb;23(2):256–260. doi: 10.1128/aac.23.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES